Literature DB >> 11190494

Recurrent ovarian clear cell carcinoma: complete remission after radiation in combination with hyperthermia; a case study and in vitro study.

M Suzuki1, Y Saga, S Tsukagoshi, N Tamura, I Sato.   

Abstract

Since clear cell carcinoma of the ovary does not respond to conventional platinum-based chemotherapy, the prognosis of recurrent tumors is especially poor. In a 51-year old female who underwent surgery for clear cell carcinoma of the ovary, a solitary metastatic carcinoma developed in the pelvic cavity seven months after the initial surgery. The patient underwent a whole pelvic irradiation at a total dose of 65 Gy combined with hyperthermia. Complete remission was achieved 46 months after treatment. A study using gynecologic carcinoma cell lines showed that the mean 50% growth inhibitory dose of radiation was 1.2 +/- 0.4 Gy in several clear cell carcinoma cell lines. The value did not significantly differ from those for serous carcinoma cell lines (2.3 +/- 1.2 Gy) and uterine cervical carcinoma cell lines (1.6 +/- 0.4 Gy). Currently, no anticancer agents are effective for clear cell carcinoma. Radiotherapy combined with hyperthermia may be effective for localized tumors.

Entities:  

Mesh:

Year:  2000        PMID: 11190494     DOI: 10.1089/cbr.2000.15.625

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  2 in total

1.  Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.

Authors:  Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Morikazu Miyamoto; Kenichi Furuya
Journal:  Int J Clin Oncol       Date:  2012-05-03       Impact factor: 3.402

2.  Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report.

Authors:  Skyler B Johnson; Joann I Prisciandaro; Jessica Zhou; Scott W Hadley; R Kevin Reynolds; Shruti Jolly
Journal:  J Appl Clin Med Phys       Date:  2014-01-06       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.